Search

everythinglearnresearchcommunity

for

Search:↓

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

The rash resolved after stopping ponatinib.

Longdan Xiegan decoction is more effective than conventional medicine for treating eczema.

Tofacitinib may help treat severe hair loss, but more research is needed.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.

Rituximab may cause skin issues, but baricitinib can help improve them.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

The FDA approved a new Pfizer drug for hair loss in teens.

Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

These new skin treatments are safer and more effective with minimal side effects.

Tofacitinib may help treat Lichen Planopilaris, but more research is needed.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.